{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000070","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.612735+00:00","generated_at":"2026-06-01T04:24:54.407530+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"AEON Biopharma stockholders elect two Class I directors and approve potential Daewoong issuance at annual meeting","bullets":["Robert Palmisano and Shelley Thunen elected as Class I directors for three-year terms ending 2027.","Stockholders approved potential issuance of 20%+ of Class A common stock to Daewoong Pharmaceuticals at below-market value, a change-of-control measure.","Ratification of KPMG LLP as auditor for fiscal 2024 passed with 25,491,112 votes for.","All three proposals received sufficient votes; broker non-votes were 675,301 on first two proposals."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000070","json":"https://secwatch.observer/filing/0001837607-24-000070.json","markdown":"https://secwatch.observer/filing/0001837607-24-000070.md","text":"https://secwatch.observer/filing/0001837607-24-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000070/0001837607-24-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000070/aeon-20240614x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:24:54.407530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}